[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-618671-105":3,"detail-sidebar-cat-0-en-105":79,"doc-detail-618671-en":129},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":72,"head_meta":74,"extra_data":76,"updated_unix":78},105,"en","cardiovascular-kidney-effects-of-dapagliflozin-in-patients-at-cardiovascular-risk-with-or-without-type-2-diabetes","Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes","","12-week sodium-glucose cotransporter-2 inhibition with dapagliflozin 10 mg daily was assessed for effects on vascular stiffness, cardiac and kidney function, and neurohormonal pathways in participants at cardiovascular risk, with or without type 2 diabetes. In a randomized, double-blind, placebo-controlled parallel study of 51 participants, vascular arterial stiffness decreased after 12 weeks. Extracellular fluid and thoracic fluid content reductions persisted, while measured glomerular filtration rate declined with compensatory sodium-handling changes. The study suggests early cardiorenal effects without established clinical protection, supporting trials in lower-risk settings.",{"@graph":14,"@context":71},[15,34,54],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cardiovascular-kidney-effects-of-dapagliflozin-in-patients-at-cardiovascular-risk-with-or-without-type-2-diabetes/618671/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":48,"encodingFormat":47,"isAccessibleForFree":49,"interactionStatistic":50},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cardiovascular-kidney-effects-of-dapagliflozin-in-patients-at-cardiovascular-risk-with-or-without-type-2-diabetes/618671.png","ImageObject",300,407,{"name":42,"@type":43},"dawugda","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-19",true,{"@type":51,"interactionType":52,"userInteractionCount":4},"InteractionCounter",{"@type":53},"ViewAction",{"@type":55,"mainEntity":56},"FAQPage",[57,63,67],{"name":58,"@type":59,"acceptedAnswer":60},"What was the primary outcome in this trial?","Question",{"text":61,"@type":62},"The primary outcome was vascular arterial stiffness, quantified using augmentation index and pulse-wave velocity.","Answer",{"name":64,"@type":59,"acceptedAnswer":65},"How did dapagliflozin affect vascular stiffness after 12 weeks?",{"text":66,"@type":62},"Dapagliflozin decreased vascular arterial stiffness, reflected by a placebo-adjusted reduction in aortic augmentation index after 12 weeks.",{"name":68,"@type":59,"acceptedAnswer":69},"What changes occurred in kidney function and sodium handling?",{"text":70,"@type":62},"Measured glomerular filtration rate decreased, alongside acute increases in proximal sodium excretion and other indices of distal sodium reabsorption, with increased urine adenosine.","https://schema.org",{"og:url":32,"og:type":73,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":75,"canonical":32},"index,follow",{"doc_id":77,"site_id":7},618671,1792449756,{"code":4,"msg":80,"data":81},"success",[82,86,90,94,99,104,109,113,118,121,125],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":83,"show_sort_weight":84,"slug":85},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":87,"show_sort_weight":88,"slug":89},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":91,"show_sort_weight":92,"slug":93},"Exam",70,"exam",{"id":95,"doc_module":4,"doc_module_name":25,"category_name":96,"show_sort_weight":97,"slug":98},5,"Comic",60,"comic",{"id":100,"doc_module":4,"doc_module_name":25,"category_name":101,"show_sort_weight":102,"slug":103},6,"Technology",50,"technology",{"id":105,"doc_module":4,"doc_module_name":25,"category_name":106,"show_sort_weight":107,"slug":108},7,"Healthcare",40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":111,"slug":112},8,30,"research-report",{"id":114,"doc_module":4,"doc_module_name":25,"category_name":115,"show_sort_weight":116,"slug":117},9,"Religion & Spirituality",20,"religion-spirituality",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":116,"slug":120},"World Cup","world-cup",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":122,"slug":124},10,"Lifestyle","lifestyle",{"id":126,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":95,"slug":128},19,"General","general",{"code":4,"msg":80,"data":130},{"doc_id":77,"user_id":131,"nickname":42,"user_avatar":132,"doc_module":4,"category_id":110,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":133,"file_id":134,"file_url":135,"file_type":136,"file_size":137,"view_count":4,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":138,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":78,"read_time":143},3985747870947,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","University of Groningen  \nCardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes  \nSridhar, Vikas S; Kugathasan, Luxcia; Lytvyn, Yuliya; Deng, Yangqing; Liu, Hongyan; Lovblom, Leif Erik; Tse, Josephine; Nardone, Massimo; Floras, John S; Osuntokun, Tosin Published in:  \nHypertension  \nDOI:  \n10.1161/HYPERTENSIONAHA.125.25955  \nIMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.  \nDocument Version  \nPublisher's PDF, also known as Version of record  \nPublication date: 2026  \nLink to publication in University of Groningen/UMCG research database  \nCitation for published version (APA):  \nSridhar, V. S. , Kugathasan, L. , Lytvyn, Y. , Deng, Y. , Liu, H. , Lovblom, L. E. , Tse, J. , Nardone, M. , Floras, J. S. , Osuntokun, T. , Tobushi, T. , Lam, R. C. Y. , Lam, B. , Stevens, J. , Burger, D. , Touw, D. J. , Heerspink, H.  \nJ. L. , Lovshin, J. A. , Perkins, B. A. , & Cherney, D. Z. I. (2026) . Cardiovascular-Kidney Effects of  \nDapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a  \nRandomized, Double-Blind, Placebo-Controlled Trial. Hypertension , 83(2), Article e25955 .  \n[https://doi.org/10.1161/HYPERTENSIONAHA.125.25955](https://doi.org/10.1161/HYPERTENSIONAHA.125.25955)  \nCopyright  \nOther than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons) .  \nThe publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: [https://www.rug.nl/library/open-access/self-archiving-pure/taverne](https://www.rug.nl/library/open-access/self-archiving-pure/taverne)amendment.  \nTake-down policy  \nIf you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.  \nDownloaded from the University of Groningen/U MCG research database (Pure): [http://www.rug. nl/research/portal. For technical reasons the](http://www.rug. nl/research/portal. For technical reasons the)[ ](http://www.rug. nl/research/portal. For technical reasons the)[number of authors shown on this cover page is limited to 10 maximum.](number of authors shown on this cover page is limited to 10 maximum.)  \nDownload date: 19-10-2026  \nDownloaded from [http://ahajournals.org by on May 20](http://ahajournals.org by on May 20), 2026  \nHypertension  \nORIGINAL ARTICLE  \n\n| Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial\u003Cbr>Vikas S. Sridhar,* Luxcia Kugathasan,* Yuliya Lytvyn, Yangqing Deng, Hongyan Liu, Leif Erik Lovblom, Josephine Tse, Massimo Nardone, John S. Floras, Tosin Osuntokun, Tomoyuki Tobushi, Ruthabella C.Y. Lam, Brian Lam, Jasper Stevens, Dylan Burger, Daan J. Touw, Hiddo J.L. Heerspink, Julie A. Lovshin, Bruce A. Perkins, David Z.I. Cherney\u003Cbr>BACKGROUND: We investigated the impact of 12 weeks of sodium-glucose cotransporter-2 inhibition (dapagliflozin 10 mg daily) on vascular stiffness, cardiac and kidney function, and neurohormonal pathways in participants at cardiovascular risk.\u003Cbr>METHODS: This randomized double-blind, parallel-group, placebo-controlled study enrolled 51 participants with at least 1 established cardiovascular condition or cardiovascular risk factor. Participants underwent 3 sequential assessments under clamped euglycemia (4–6 mmol/L): at baseline, at 1 week and 12 weeks of treatment. The primary outcome was vascular arterial stiffness, quantified as augmentation index and pulse-wave velocity. Secondary","cbCaimthRX1F3Gjx","https://ap.wps.com/l/cbCaimthRX1F3Gjx","pdf",1298364,17,"English","# Background\n# Methods\n# Results\n# Conclusions\n# Registration\n# Key Words","[{\"question\":\"What was the primary outcome in this trial?\",\"answer\":\"The primary outcome was vascular arterial stiffness, quantified using augmentation index and pulse-wave velocity.\"},{\"question\":\"How did dapagliflozin affect vascular stiffness after 12 weeks?\",\"answer\":\"Dapagliflozin decreased vascular arterial stiffness, reflected by a placebo-adjusted reduction in aortic augmentation index after 12 weeks.\"},{\"question\":\"What changes occurred in kidney function and sodium handling?\",\"answer\":\"Measured glomerular filtration rate decreased, alongside acute increases in proximal sodium excretion and other indices of distal sodium reabsorption, with increased urine adenosine.\"}]","Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes | PDF",43]